Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster presentation highlights data in primary human hepatocytes demonstrating the high specificity and lack of detectable off-target editing for PBGENE-HBV at therapeutically relevant doses. The poster will also showcase non-human primate data demonstrating good tolerability of a multi-dosing approach for the treatment of chronic hepatitis B.
愛文思控股公司（NASDAQ:DTIL）是一家先進的基因編輯公司，利用其新穎的專有ARCUS平台開發體內基因編輯療法，今天宣佈該公司將在歐洲肝病協會會議（EASL）上展示其PBGENE-HBV臨床候選的臨床前數據，突出ARCUS的差異化能力，實現高效、持久和靶向消除編輯。海報展示了在治療量下，PBGENE-HBV在初級人肝細胞中具有高特異性和不可檢測的離靶編輯數據。此外，海報還展示了非人靈長類數據，證明了多劑量方法治療慢性乙肝的良好耐受性。
譯文內容由第三人軟體翻譯。